David Wilson

England

Carpmaels & Ransford LLP · David is a consultant in the Dispute Resolution team at Carpmaels & Ransford. He previously led the team and has over 30 years’ experience of handling complex patent disputes involving multi-jurisdictional litigation between major science and technology companies, in particular in the pharmaceutical and telecommunications sectors. He has a wealth of experience defending and bringing claims for corporations in patent infringement and revocation actions both in the UK and across Europe. A source describes him as “scientifically strong and an experienced and tough litigator.” (Chambers UK, 2020). David has represented clients in some of the UK’s largest patent cases both at first instance and appeal (including successfully acting for his clients all the way up to the Supreme Court in what is now the leading UK case on claim construction). David is also registered as a legal representative at the UPC and hence able to represent clients in pan-European patent litigation at this new court. He has particular expertise in litigating patent-related disputes where they arise in the context of existing license agreements and in negotiating high-value licenses and settlement agreements for his clients. “[David] is entrusted by science and technology players to assist with multi-jurisdictional litigation”…and “has a proven track record in negotiating high-value licenses and settlement agreements.” (Legal 500 UK, 2024). He is known for “regularly engaging in multi-jurisdictional litigation between companies in the pharmaceutical and telecoms sectors, David makes even the most complex patent disputes look easy” (IAM Patent 1000, 2020). Clients in Chambers UK, 2021 comment that “he has amassed a lot of good experience working for innovators” and they were “impressed by his calm demeanour.” During his career he has advised on ground-breaking cases which include securing victory for his clients in Kirin-Amgen, Inc. v Hoechst Marion Roussel Ltd, the UK’s leading authority on claim construction and achieving success for his client FibroGen in the Court of Appeal case of FibroGen v Akebia – the leading case on the assessment of sufficiency of functionally limited claims. He was awarded IP Lawyer of the Year: Pharmaceuticals in the 2020 LMG Awards and European SPC Litigator of the Year in the 2021 LMG Awards.

England